EFFECTIVENESS OF COMBINED INDUCTION CHEMOTHERAPY AND RADIOTHERAPY IN ADVANCED NASOPHARYNGEAL CARCINOMA

被引:93
作者
DIMERY, IW
PETERS, LJ
GOEPFERT, H
MORRISON, WH
BYERS, RM
GUILLORY, C
MCCARTHY, K
WEBER, RS
HONG, WK
机构
[1] UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77025 USA
[2] UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEAD & NECK SURG, HOUSTON, TX 77025 USA
[3] UNIV TEXAS, MD ANDERSON CANC CTR, DIV RADIOTHERAPY, HOUSTON, TX 77025 USA
关键词
D O I
10.1200/JCO.1993.11.10.1919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This prospective trial was conducted with the goal of achieving an improvement in both overall and progression-free survival in previously untreated patients with stage IV nasopharyngeal carcinoma who received an induction chemotherapy regimen of fluorouracil (5-FU) and cisplatin followed by radiotherapy. Patients and Methods; From January 1985 to January 1990, 47 patients with T1-4N2-3M0 squamous cell carcinoma of the nasopharynx were treated at The University of Texas M.D. Anderson Cancer Center with two to three cycles of 5-FU (1,000 mg/m2 continuous infusion per day × 5 days) plus cisplatin (100 mg/m2 continuous infusion on day 1 only) followed by radiotherapy using the conventional time/dose schedule. Results: The response rate to chemotherapy was 93.2% (20.5% complete response [CR]; 72.7% partial response [PR]), and the overall CR rate after radiotherapy was 86%. With a median follow-up period of 53 months, the 2-, 4-, and 6-year survival rates were 80%, 71.6%, and 67.4%; the overall treatment failure rate was 27%. Treatment was well tolerated and without significant acute or chronic toxic effects. Conclusion: The results of this prospective study demonstrate that 5-FU plus cisplatin followed by radiotherapy can induce a durable remission in a high proportion of patients with poor-prognosis stage IV nasopharyngeal carcinoma.
引用
收藏
页码:1919 / 1928
页数:10
相关论文
共 60 条
[1]   DISTANT METASTASES OF NASOPHARYNGEAL CARCINOMA - A STUDY OF 256 MALE-PATIENTS [J].
AHMAD, A ;
STEFANI, S .
JOURNAL OF SURGICAL ONCOLOGY, 1986, 33 (03) :194-197
[2]   EXCELLENT RESPONSE TO CIS-PLATINUM BASED CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PREVIOUSLY UNTREATED ADVANCED NASOPHARYNGEAL CARCINOMA [J].
ALKOURAINY, K ;
CRISSMAN, J ;
ENSLEY, J ;
KISH, J ;
KELLY, J ;
ALSARRAF, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (04) :427-430
[3]   CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA - A RADIATION-THERAPY ONCOLOGY GROUP-STUDY [J].
ALSARRAF, M ;
PAJAK, TF ;
COOPER, JS ;
MOHIUDDIN, M ;
HERSKOVIC, A ;
AGER, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) :1342-1351
[4]   CONCOMITANT BOOST RADIOTHERAPY SCHEDULES IN THE TREATMENT OF CARCINOMA OF THE OROPHARYNX AND NASOPHARYNX [J].
ANG, KK ;
PETERS, LJ ;
WEBER, RS ;
MAOR, MH ;
MORRISON, WH ;
WENDT, CD ;
BROWN, BW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06) :1339-1345
[5]  
ARMAND JP, 1988, P ASCO, V7, P151
[6]   HIGH COMPLETE RESPONSE IN ADVANCED NASOPHARYNGEAL CARCINOMA WITH BLEOMYCIN, EPIRUBICIN, AND CISPLATIN BEFORE RADIOTHERAPY [J].
BACHOUCHI, M ;
CVITKOVIC, E ;
AZLI, N ;
GASMI, J ;
CORTESFUNES, H ;
BOUSSEN, H ;
RAHAL, M ;
KALIFA, C ;
SCHWAAB, G ;
ESCHWEGE, F ;
WIBAULT, P ;
ARMAND, JP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07) :616-620
[7]  
BACHOUCHI M, 1989, P AN M AM SOC CLIN, V8, P173
[8]  
CHATANI M, 1986, CANCER, V57, P2267, DOI 10.1002/1097-0142(19860615)57:12<2267::AID-CNCR2820571205>3.0.CO
[9]  
2-C
[10]  
CLARK JR, 1988, SEMIN ONCOL, V15, P35